Nouvelle déclaration d'incident
No de la demande: 2020-3427
Numéro de référence du titulaire d'homologation: 2020-US-010842
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: TEXAS
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-83
Nom du produit: Hartz UltraGuard Flea and Tick Collar for Cats and Kittens
Autre (préciser)
CollarOui
Inconnu
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Domestic Longhair
1
Femme
2
5
lbs
Cutanée
>8 hrs <= 24 hrs / >8 h <= 24 h
>2 hrs <=8 hrs / > 2 h < = 8 h
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On approximately 27-Apr-2020, a 2 year old, approximately 5 pound, neutered, female, Domestic Longhair cat, in unknown condition, with concomitant medical condition of fleas, was administered 1 collar of Hartz UltraGuard Flea and Tick Collar for Cats and Kittens (non-specific) (Tetrachlorvinphos) via the topical route by the animal owner. Approximately four hours post application, the cat developed lethargy. On 28-Apr-2020, the cat was found dead and was buried. No other signs were noted prior to death. The cat had was not evaluated by a veterinarian and no treatments were performed. The cat was already buried so a necropsy was not performed. The animal owner also applied unspecified Hartz Flea and Tick Collars to 11 other cats and 2 dogs in the home on 27-Apr-2020. All 13 pets developed lethargy and vomiting approximately four hours later. The collars were removed on 04-May-2020 and the clinical signs resolved approximately one hour later.
Mort
Assessment: The product is considered to have a wide margin of safety in cats and is not systemically absorbed following application. Signs of dermal irritation and GI upset may occur. Sudden death is not expected following use. Other causes should be considered including underlying cardiac disease, severe flea bite anemia, unknown trauma, and other exposures. Without a necropsy the cause of death remains unknown. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.